Neurofeedback for Nociplastic Pain in Rheumatoid Arthritis (NECTAR)
RecruitingNot applicableNCT06240299
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Rheumatoid arthritis is an autoimmune condition, causing inflammation and pain. Yet pain may persist even when inflammation has been treated. This residual pain, called nociplastic pain, has symptoms of a chronic pain condition called fibromyalgia. There are few effective therapies to address this residual pain. Published literature shows that fibromyalgia can be treated by neurofeedback, a noninvasive method that is based on the voluntary modulation of cortical activity. In this pilot study, the investigators want to test the effect of neurofeedback on the fibromyalgia component of pain in rheumatoid arthritis, and also to investigate its effects on related symptoms such as fatigue and sleep disturbance.
Study details
- Official title
- Neurofeedback for Nociplastic Pain in Rheumatoid Arthritis
- Interventions
- Procedure: Neurofeedback
- Sponsor
- NHS Greater Glasgow and Clyde
- Collaborators
- University of Glasgow
- Start date
- 2024-06-24
- Primary completion
- 2027-01-29
- Sex
- All
- Age range
- from 18 Years to 75 Years
- Results posted
- No results posted in this snapshot
- Countries
- United Kingdom
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Fulfilment of the ACR/EULAR Classification Criteria for rheumatoid arthritis (RA) * Fulfilment of the American College of Rheumatology criteria for chronic widespread pain * Stable disease (swollen joint count ≤1 and CRP ≤10) * Has normal or corrected to normal vision and hearing abilities * Right-handed (to reduce baseline motor response test heterogeneity) * Pain intensity equal or larger than 4 on the Visual Numerical Scale (0 no pain, 10, max pain imaginable) Exclusion Criteria: * Unable to understand the task. * Unable to provide a written informed consent. * Unable to understand English. * Major confounding neurological diseases including Multiple Sclerosis, Stroke, Traumatic Brain Injury, Parkinson's Disease, and Alzheimer's Disease) * Medical or psychiatric conditions that in the judgment of study personnel would preclude participation in the study (psychosis, suicidal ideation etc) * Under active management of pain team (changing medications, other non pharmacological pain treatment) * Involved in other interventional experimental studies
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06240299